人乳头瘤病毒治疗性疫苗临床试验研究进展  

Current status of clinical trials of HPV therapeutic vaccines

作　　者：王泯驿 寸怡娜[1] Wang Minyi;Cun Yina(Institute of Medical Biology,Chinese Academy of Medical Sciences&Peking Union Medical College,Kunming 650118,China)

机构地区：[1]中国医学科学院北京协和医学院医学生物学研究所,昆明650118

出　　处：《中华预防医学杂志》2023年第10期1647-1654,共8页Chinese Journal of Preventive Medicine

基　　金：云南省基础研究专项(202201AT070235);2022年度云南省基础研究计划重点项目(202101AS070205)。

摘　　要：子宫颈癌已经成为严重威胁女性健康的公共卫生问题,人乳头瘤病毒(HPV)感染是子宫颈癌最主要致病因素。为了预防HPV感染,目前使用的预防性疫苗主要通过诱导宿主产生体液免疫反应,从而生成中和抗体。相较之下,HPV治疗性疫苗的设计目标是诱导宿主产生以Th1为主的细胞免疫应答,并清除已有的病毒感染并延缓或抑制肿瘤的发展。目前,已有多种基于不同机制和技术的HPV治疗性疫苗进入临床试验阶段。本文对上述疫苗的临床试验进展进行了梳理和总结,以期为我国HPV治疗性疫苗的研发工作提供参考。Cervical cancer mainly caused by human papillomavirus(HPV)infection has become a public health issue,which seriously threatens women′s health.To prevent HPV infection,the currently used prophylactic vaccines mainly induce a humoral immune response in the host,thereby generating neutralizing antibodies.In contrast,the design goal of therapeutic HPV vaccines is to induce a cell-mediated immune response in the host,primarily driven by Th1 cells,aiming to clear existing viral infections and slow down or inhibit tumor progression.Currently,several therapeutic HPV vaccines based on different mechanisms and techniques have entered clinical trials.This review will summarize the progress of these clinical trials,providing reference for the research and development of therapeutic HPV vaccines.

关 键 词：人乳头瘤病毒 宫颈肿瘤 治疗性疫苗 临床试验 

分 类 号：R392[医药卫生—免疫学]